ArticleFrontiers in endocrinology2026
Hybrid PET/fMRI reveals interactive effects of T2DM and MCI on cerebral glucose metabolism and ALFF.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 diabetes mellitus (T2DM) is frequently associated with mild cognitive impairment (MCI), significantly impacting patient health, quality of life, and healthcare systems. However, the precise cerebral metabolic and functional alterations resulting from the interaction between T2DM and MCI remain incompletely understood. Methods: Fifty-four participants were categorized into four groups based on T2DM and MCI status. Hybrid positron emission tomography/functional magnetic resonance imaging (PET/fMRI) was used to assess cerebral glucose metabolism and the amplitude of low-frequency fluctuations (ALFF). A two-way analysis of variance evaluated the main and interactive effects of T2DM and MCI on these measures. Partial correlation analysis examined the associations between clinical variables and the observed metabolic/ALFF abnormalities. Results: Alterations in cerebral glucose metabolism in T2DM-MCI patients were primarily attributable to T2DM, with significant effects observed in the frontal, occipital, and temporal lobes, as well as subcortical regions. Both main and interactive effects of T2DM and MCI on ALFF were significant. Notably, antagonistic interactions were identified in the right superior frontal gyrus (medial orbital part) and middle frontal gyrus, suggesting that T2DM suppresses spontaneous neural activity in these regions, whereas MCI enhances it. T2DM was the principal factor influencing both metabolic and ALFF changes in the right inferior frontal gyrus (pars orbitalis). Montreal cognitive assessment scores, fasting blood glucose, and 2-hour postprandial blood glucose levels significantly correlated with neural activity alterations in regions affected by the main or interactive effects. Conclusion: This hybrid PET/fMRI study identifies frontal regions where aberrant metabolic and ALFF patterns are associated with T2DM-related cognitive decline, suggesting their potential as early neuroimaging biomarkers. These findings provide new mechanistic insights and highlight possible therapeutic targets for this comorbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.